Cagrilintide + Semaglutide Blend

100% delivery

  • Done Satisfaction Guaranteed
  • Done No Hassle Refunds
  • Done Secure Payments
GUARANTEED SAFE CHECKOUT
  • Visa Card
  • MasterCard

Description

For Research Use Only. Not for Human or Veterinary Use.
Weight Management10mg*10vialsHPLC ≥ 99%COA per batch

Cagrilintide 5mg+Semaglutide 5mg

Cagrilintide,Semaglutide

Specifications:
COA for Cagrilintide 5mg + Semaglutide 5mg not yet published

Contact us for current batch testing data on this specification.

Cagrilintide 5mg+Semaglutide 5mg
TL;DR

Cagrilintide 5 mg + Semaglutide 5 mg is a dual-peptide lyophilized research product containing 5 mg of Cagrilintide and 5 mg of Semaglutide in a single vial. Cagrilintide is a long-acting amylin analogue with activity at amylin-family receptors, while Semaglutide is a long-acting GLP-1 receptor analogue. The product is intended for laboratory research use only.

Overview

Cagrilintide is a long-acting amylin analogue and dual amylin/calcitonin receptor agonist; semaglutide is a GLP-1 analogue. The two peptides act at distinct GPCRs and are supplied together as separate lyophilized reference materials for laboratory research.

Each lot is supplied with batch-level analytical documentation. Identity, purity and net peptide content are recorded on the COA, with HPLC and mass-spectrometric confirmation for both peptides.

This listing is for a single-vial research product containing 5 mg of Cagrilintide and 5 mg of Semaglutide in a combined lyophilized formulation. The two peptides are co-formulated in the same vial and are not provided as separate vials or as a single fused peptide. Cagrilintide is based on a 37-residue amylin backbone with N-terminal C20 diacid lipidation, while Semaglutide is a 31-residue GLP-1(7–37) analogue with Aib8, Arg34, and Lys26 acylation. The combined formulation is intended for laboratory research involving amylin-family receptors and GLP-1R.

Cagrilintide is a lipidated analogue of human amylin. Relative to the native 37-residue sequence it carries N14E and V17R (helix-stabilizing salt bridge), proline substitutions at positions 25, 28, 29 and 37 (lower β-sheet propensity), a Cys2–Cys7 disulfide, C-terminal amidation, and N-terminal acylation of Lys1 with a C20 fatty diacid via a γ-glutamyl linker. Cryo-EM structures show an amylin-like binding mode at AMY1R, AMY2R, AMY3R and CTR.

Semaglutide is a synthetic analogue of human GLP-1(7–37). It contains two backbone substitutions versus native GLP-1 (Aib8; Arg34) and is acylated at Lys26 with a C18 diacid linked through γGlu and two AEEA spacers. The Aib8 substitution reduces cleavage by dipeptidyl peptidase-4. The peptide is 31 amino acids and is used in the laboratory as a long-acting GLP-1 receptor reference agonist.

Each batch is HPLC-purified and mass-confirmed. Identity, chromatographic purity and net peptide content for both components are stated on the lot COA. This kit is supplied for in-vitro and analytical laboratory work only.

Key Highlights

  • Cagrilintide: AMY1R / AMY2R / AMY3R / CTR agonist (amylin-backbone DACRA)
  • Semaglutide: GLP-1 receptor analogue, 31 residues, Aib8 / Arg34 / Lys26-acyl
  • ≥99% purity verified by HPLC and mass spectrometry (per component, per lot)
  • Full batch traceability; COA issued for every lot
  • Third-party tested, research-grade raw material

Safety & Side Effects

Cagrilintide 5 mg + Semaglutide 5 mg is a dual-peptide lyophilized research product containing 5 mg of Cagrilintide and 5 mg of Semaglutide in a single vial. Cagrilintide is a long-acting amylin analogue with activity at amylin-family receptors, while Semaglutide is a long-acting GLP-1 receptor analogue. The product is intended for laboratory research use only. When used in research, Cagrilintide 5mg + Semaglutide 5mg should be handled in a qualified laboratory setting, and its safety profile should be interpreted strictly within the experimental context in which it was studied.

Published cagrilintide 5mg + semaglutide 5mg side effects data are limited to experimental models and are specific to the dose, route, and study design employed. Investigators should account for metabolic regulation and energy expenditure readouts and any off-target effects relevant to the compound’s mechanism when designing a study.

For authoritative safety and toxicology references, consult peer-reviewed databases (PubMed, PubChem) and review the batch Certificate of Analysis before designing your protocol.

Dosage & Protocol

There is no standardized human dosage for Cagrilintide 5mg + Semaglutide 5mg; it is supplied strictly for laboratory research. Reported cagrilintide 5mg + semaglutide 5mg dosage values in the literature are derived from preclinical studies and are specific to the study model, route, and experimental design.

Research protocols typically document cagrilintide 5mg + semaglutide 5mg dosage together with reconstitution method, storage conditions, and analytical confirmation of identity (CAS 1415456-99-3 / 910463-68-2, molecular formula C194H312N54O59S2 / C187H291N45O59, molecular weight 4409 g/mol / 4113.6 g/mol). Because dose-response relationships may not scale across models, investigators should base their design on peer-reviewed methods rather than informal community reports.

Always confirm the exact strength, purity, and lot-specific data from the batch COA before weighing or reconstituting your sample.

Comparison

PeptideReceptorsCore Characteristic
Cagrilintide + SemaglutideAMYR/CTR + GLP-1RTwo-peptide kit; amylin analogue plus GLP-1 analogue
CagrilintideAMY1R / AMY2R / AMY3R / CTRLong-acting lipidated amylin analogue
SemaglutideGLP-1RLong-acting GLP-1(7–37) analogue
RetatrutideGLP-1R / GIPR / GCGRTriple-receptor agonist

How to Order

1

Enquiry

Send product code, strength and quantity for a fast quote.

2

Quotation

Price, lead time and specification confirmed.

3

QC & COA

Batch tested by HPLC/LC-MS; COA issued.

4

Delivery

Tracked worldwide shipping.

Specifications

Product nameCagrilintide 5mg+Semaglutide 5mg
Product codeCS10
Specification10mg*10vials
CAS number1415456-99-3 / 910463-68-2
Molecular formulaC194H312N54O59S2 / C187H291N45O59
Molecular weight4409 g/mol / 4113.6 g/mol
Purity≥99%
Physical FormTwo vials of lyophilized white solid powder
SolubilitySoluble in bacteriostatic water (reconstitute each vial separately)
Amino Acid CountCagrilintide 37 residues; Semaglutide 31 residues

Applications

ResearchLaboratoryAcademicDrug Discovery

Packaging & Shipping

Available pack sizes

10mg*10vials

Shipping

WorldwideCold ChainExpress

Storage & Handling

Store lyophilized at −20 °C, protected from light and moisture. Bring each vial to room temperature before opening. Refrigerate after reconstitution and avoid repeated freeze–thaw cycles. For laboratory research use only.

Product Information Q&A

What purity is your Cagrilintide 5mg+Semaglutide 5mg?

HPLC ≥99%, with mass-spec confirmation and a Certificate of Analysis provided for every batch.

What pack sizes are available?

Available options include: 10mg*10vials. Custom packaging is available on request.

Can I order bulk quantities?

Yes. We supply from research samples to bulk orders with scalable manufacturing and stable supply.

What does “Research Use Only” mean?

These peptides are supplied for laboratory research only. They are not for human or veterinary administration, and they are not a medicine, food, or cosmetic.

How should the kit be shipped and stored?

Shipped as lyophilized powder. Store dry powder at −20 °C, protected from light and humidity. Equilibrate to room temperature before opening. Keep reconstituted solutions refrigerated and do not freeze–thaw repeatedly.